The frequency and impact of ROS1 rearrangement on clinical outcomes in never smokers with lung adenocarcinoma
Hye Ryun Kim(Yonsei University), Byoung Chul Cho(Yonsei University)
Cited by 124
Related Papers
Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study
|Annals of Oncology|2023|384
Genome-wide identification of differentially methylated promoters and enhancers associated with response to anti-PD-1 therapy in non-small cell lung cancer
|Experimental & Molecular Medicine|2020|282
Repotrectinib Exhibits Potent Antitumor Activity in Treatment-Naïve and Solvent-Front–Mutant ROS1-Rearranged Non–Small Cell Lung Cancer
|Clinical Cancer Research|2020|115
Role and Function of O-GlcNAcylation in Cancer
|Cancers|2021|93